Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON: Bevacizumab + Temozolomide ± Irinotecan in Relapsed/Refractory Neuroblastoma
2024-518931-12-00Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised trial of bevacizumab, temozolomide, irinotecan and Dinutuximab beta in neuroblastoma (4 arms), sponsored by University of Birmingham. Started Nov 2024; status: completed.
02
Drugs
bevacizumabtemozolomideirinotecanDinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2024-518931-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518931-12-00.